VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of the Medical University of Vienna, who gave Oncology Times reporter Sarah Maxwell the latest data on the clinical potential of bone-directed therapies.
You may also like...
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer 8 Jun, 2018 Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer 25 Jul, 2018 Combined Intracavitary/Interstitial Brachytherapy: New benchmark for Cervical Cancer 5 May, 2015 Breast cancer chemoprevention: meta-analysis shows SERMs are highly effective 1 May, 2013
- Previous story BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer
- Next story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014